- Home
- LSPD vs DNTH Comparison
LSPD vs DNTH Comparison
Compare LSPD & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSPD
- DNTH
- Stock Information
- Founded
- LSPD 2005
- DNTH 2015
- Country
- LSPD Canada
- DNTH United States
- Employees
- LSPD N/A
- DNTH N/A
- Industry
- LSPD
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- LSPD
- DNTH Health Care
- Exchange
- LSPD Nasdaq
- DNTH Nasdaq
- Market Cap
- LSPD 1.6B
- DNTH 1.4B
- IPO Year
- LSPD 2020
- DNTH N/A
- Fundamental
- Price
- LSPD $12.89
- DNTH $38.40
- Analyst Decision
- LSPD Hold
- DNTH Strong Buy
- Analyst Count
- LSPD 14
- DNTH 10
- Target Price
- LSPD $13.46
- DNTH $68.00
- AVG Volume (30 Days)
- LSPD 723.7K
- DNTH 485.3K
- Earning Date
- LSPD 11-06-2025
- DNTH 11-05-2025
- Dividend Yield
- LSPD N/A
- DNTH N/A
- EPS Growth
- LSPD N/A
- DNTH N/A
- EPS
- LSPD N/A
- DNTH N/A
- Revenue
- LSPD $1,157,458,000.00
- DNTH $3,078,000.00
- Revenue This Year
- LSPD $14.32
- DNTH N/A
- Revenue Next Year
- LSPD $11.78
- DNTH N/A
- P/E Ratio
- LSPD N/A
- DNTH N/A
- Revenue Growth
- LSPD 14.24
- DNTH N/A
- 52 Week Low
- LSPD $7.34
- DNTH $13.37
- 52 Week High
- LSPD $18.96
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- LSPD 55.87
- DNTH 66.85
- Support Level
- LSPD $11.21
- DNTH $32.56
- Resistance Level
- LSPD $13.72
- DNTH $37.50
- Average True Range (ATR)
- LSPD 0.57
- DNTH 1.80
- MACD
- LSPD 0.13
- DNTH 0.38
- Stochastic Oscillator
- LSPD 63.27
- DNTH 95.75
About LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.